Enkephalins

Overview

The enkephalins are the smallest endogenous opioid peptides, consisting of just five amino acids. Met-enkephalin (Tyr-Gly-Gly-Phe-Met) and leu-enkephalin (Tyr-Gly-Gly-Phe-Leu) were discovered in 1975 by John Hughes and Hans Kosterlitz at the University of Aberdeen, who isolated these peptides from pig brain based on their ability to mimic morphine's effects in a bioassay system. This landmark discovery established the existence of an endogenous opioid system and earned Kosterlitz and colleagues the Lasker Award.

The name "enkephalin" derives from the Greek en kephale ("in the head"), reflecting their initial isolation from brain tissue. Their discovery solved a long-standing puzzle in pharmacology: why the mammalian brain possesses high-affinity receptors for opium alkaloids, plant-derived compounds that animals would never naturally encounter. The answer was that opioid receptors evolved to respond to endogenous peptide ligands, of which the enkephalins were the first identified.

Enkephalins are the preferred endogenous ligands of the delta-opioid receptor (DOR), though they also bind mu-opioid and kappa-opioid receptors with lower selectivity. They are derived from two precursor proteins: proenkephalin A (which produces both met- and leu-enkephalin) and prodynorphin (which produces leu-enkephalin).

Structure and Molecular Forms

Met-enkephalin:

• Sequence: Tyr-Gly-Gly-Phe-Met
• Molecular weight: 573.7 Da
• Precursor: Proenkephalin A (contains 4 copies of met-enkephalin plus extended forms)
• Relative abundance: More abundant than leu-enkephalin in most tissues

Leu-enkephalin:

• Sequence: Tyr-Gly-Gly-Phe-Leu
• Molecular weight: 555.6 Da
• Precursors: Proenkephalin A (1 copy) and prodynorphin (as the N-terminal sequence of Dynorphin A)

Extended enkephalins from proenkephalin A:

• Met-enkephalin-Arg6-Phe7 (heptapeptide)
• Met-enkephalin-Arg6-Gly7-Leu8 (octapeptide)
• Peptide E (25 amino acids, contains met-enkephalin)
• Peptide F (18 amino acids, contains met-enkephalin)

The Tyr-Gly-Gly-Phe tetrapeptide motif at the N-terminus is the minimal pharmacophore required for opioid receptor binding. The fifth residue (Met or Leu) modulates receptor subtype selectivity and metabolic stability.

Receptor Pharmacology

Delta-Opioid Receptor (DOR) Selectivity

Enkephalins bind DOR with nanomolar affinity and approximately 10-fold preference over mu-opioid receptors:

Receptor	Met-Enkephalin Ki	Leu-Enkephalin Ki
Delta (DOR)	~1-2 nM	~2-5 nM
Mu (MOR)	~10-20 nM	~20-40 nM
Kappa (KOR)	~1,000+ nM	~1,000+ nM

DOR signaling:

• Gi/o-coupled: inhibits adenylyl cyclase, activates GIRK potassium channels, inhibits voltage-gated calcium channels
• Reduces presynaptic neurotransmitter release (particularly glutamate and Substance P in pain circuits)
• Activates MAPK/ERK signaling through both G-protein and beta-arrestin pathways
• DOR activation produces analgesia, anxiolysis, antidepressant-like effects, and cardioprotection

Comparison with Other Endogenous Opioids

The three major endogenous opioid peptide families exhibit distinct receptor preferences:

• Enkephalins: Delta-preferring (analgesic, mood-modulating)
• Beta-endorphin: Mu-preferring (euphorigenic, analgesic)
• Dynorphin: Kappa-preferring (dysphoric, stress-related)

This receptor selectivity pattern enables the endogenous opioid system to produce distinct behavioral and physiological outcomes depending on which peptide family is activated by a given stimulus.

Distribution and Functions

Central Nervous System

Enkephalins and proenkephalin-derived peptides are among the most widely distributed neuropeptides in the brain:

Pain modulation:

• Dense enkephalinergic innervation of the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), key nodes in descending pain inhibitory pathways
• Spinal dorsal horn enkephalin interneurons gate pain transmission according to the gate control theory framework
• Enkephalin release in these circuits mediates endogenous analgesia triggered by stress, acupuncture, placebo, and exercise

Reward and motivation:

• Enkephalins in the nucleus accumbens and ventral pallidum modulate hedonic responses to food, social interaction, and other natural rewards
• Met-enkephalin in the ventral striatum participates in "liking" responses to pleasurable stimuli
• DOR signaling modulates motivation and reward learning

Mood regulation:

• DOR activation produces anxiolytic and antidepressant-like effects in animal models
• Enkephalin levels in limbic circuits (amygdala, hippocampus, prefrontal cortex) modulate emotional processing
• DOR knockout mice exhibit increased anxiety and depressive-like behavior

Peripheral Nervous System

• Enkephalin-containing neurons in the enteric nervous system regulate gastrointestinal motility and secretion
• Peripheral sensory neurons express opioid receptors that can be activated by locally released enkephalins during inflammation, providing peripheral analgesia

Immune System

• Enkephalins modulate immune function through opioid receptors on lymphocytes, monocytes, and natural killer cells
• Met-enkephalin has been shown to enhance natural killer cell activity and modulate cytokine production
• The immune-modulatory effects of enkephalins represent a peptidergic link between the nervous and immune systems

Metabolism and Degradation

Enkephalins are rapidly degraded by two principal membrane-bound peptidases:

• Neutral endopeptidase (NEP/neprilysin/CD10): Cleaves the Gly3-Phe4 bond
• Aminopeptidase N (APN/CD13): Cleaves the Tyr1-Gly2 bond

Plasma Half-life is measured in seconds (~2-10 seconds), making enkephalins among the most rapidly metabolized neuropeptides. This extreme metabolic lability ensures that enkephalin signaling remains spatially and temporally precise, confined to the immediate vicinity of release sites.

Enkephalinase Inhibitors

The rapid degradation of enkephalins has motivated the development of enkephalinase inhibitors — compounds that prevent enkephalin breakdown, thereby enhancing endogenous opioid tone:

• Dual NEP/APN inhibitors (DENKIs): Compounds such as RB-101 and kelatorphan inhibit both degradative enzymes simultaneously, producing analgesic and anxiolytic effects mediated by elevated endogenous enkephalin levels
• Thiorphan: A selective NEP inhibitor used experimentally
• Racecadotril (acetorphan): A NEP inhibitor approved in some countries for secretory diarrhea; its mechanism involves reducing intestinal enkephalin degradation

This approach offers potential advantages over exogenous opioid administration, including reduced tolerance development and abuse liability, because it amplifies the endogenous opioid signal rather than providing continuous exogenous receptor stimulation.

Dosing Protocols

As endogenous opioid peptides, enkephalins (met-enkephalin and leu-enkephalin) are not typically administered exogenously in clinical practice. They are primarily studied as components of the endogenous pain modulation system and through receptor-targeted interventions (delta-opioid receptor agonists). Their extremely rapid degradation by enkephalinases (aminopeptidase N and neutral endopeptidase) in vivo limits direct therapeutic utility. Research approaches focus on enkephalinase inhibitors to enhance endogenous enkephalin levels rather than exogenous enkephalin administration.

Clinical Significance

Enkephalins are not administered as therapeutic agents due to their rapid degradation. However, their biology informs several therapeutic strategies:

• Enkephalinase inhibitors: As described above, for pain management with potentially reduced abuse liability
• DOR-selective agonists: Investigated for analgesia, depression, and anxiety without the respiratory depression and constipation associated with mu-opioid agonists
• Biomarkers: Proenkephalin A (PENK), a stable processing fragment, is investigated as a biomarker for kidney function and critical illness severity
• Cancer immunology: Met-enkephalin (opioid growth factor) has been investigated for anti-proliferative effects in certain cancers via the opioid growth factor receptor (OGFr)

The enkephalin system remains a foundational element in understanding endogenous pain control, reward, and affect regulation, and continues to inform the development of next-generation analgesics and psychiatric therapeutics.